SAGE Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
With that, I'm Salveen Richter, Biotechnology Analyst for Goldman. I'm just going to start with the disclosure for the day. We are required to make certain disclosures in public appearances about Goldman Sachs' relationships with companies that we discussed. The disclosures related to investment banking [relate to] compensation (inaudible) of ownership. We're prepared to read aloud disclosures for any issuer upon request. However, these disclosures are available on our most recent (inaudible) reports available to you as clients on our firm's portal.
With that, I am pleased to have the team from Sage. We have Jeff Jonas, CEO; and Kimi Iguchi, CFO. Thank you for joining us this morning.
Questions & Answers
And let's start. You're about to launch your first drug, ZULGRESSO -- ZULRESSO, in postpartum depression.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |